Kornimate/medical-research-clean huggingface dataset:
the effects of rasagiline on cognitive deficits associated with parkinson's disease

Conditions: Parkinson's Disease

Summary: the objective of the study is to assess the effects of rasagiline on cognitive functions in patient with parkinson's disease. patients on any dopaminergic medications will be assigned to receive rasagiline 1 mg or placebo over 3 months. cognitive functions will be assessed by selected neuropsychological tests representing each cognitive domain.

the primary objective of this study is to assess the effects of rasagiline on cognitive deficits in non-demented patients with pd. the secondary objective is to assess affective changes in this patient population. this will be a randomized, double-blind, placebo controlled study in 1-3 centers. patients will be recruited from the movement disorders outpatients clinic, department of neurology, istanbul faculty of medicine, dokuz eylul university and marmara university. eligible patients will be randomly assigned to rasagiline 1 mg or placebo. patients will be treated with the study medication over 3 months. cognitive and behavioral assessments will be performed at baseline, at 4 weeks and at the end of the study, at 12 weeks. a total of 40 pd patients with cognitive deficits, but without dementia will be recruited. no sample size calculation will be performed, a sample of convenience will be used.

Eligibility criteria:
inclusion criteria: 1. male and female patients of any age 2. diagnosis of idiopathic pd according to the uk brain bank criteria for the clinical diagnosis of pd. 3. patients with cognitive impairment associated with pd, defined as: 1. subjective complaints of impaired cognitive functions such as forgetfulness, word finding difficulties or inattentiveness 2. presence of objectively demonstrable cognitive deficits in at least 2 out of the 4 cognitive domains typically impaired in pd. these include attention, executive functions, memory and visuo-spatial functions. the performance in the following test scores must be 1.5 standard deviations below the mean normative score for age and education of the patient: digit span for attention, letter fluency test for executive function, logical memory sub-scale from the wechsler memory scale-revised and line orientation test for visuo-spatial function. 4. patients with a hoehn and yahr stage i-iii when "on" 5. literate patients who are able to follow test instructions exclusion criteria: 1. diagnosis of dementia due to pd according to dsm iv criteria 2. diagnosis of current major depressive episode according to dsm iv criteria 3. presence of any other neurodegenerative disorder other than pd 4. presence of any unstable or untreated systemic disorder such as diabetes, cardiac failure, renal failure 5. use of any prohibited concomitant medication

Keywords: parkinson's disease rasagiline cognition mao-b
swab sample collection for the detection of bacterial proteases

Conditions: Chronic Wounds

Summary: the objective of this study is to collect wound exudate (fluid) swab samples from subjects who have wounds that show clinical signs of infection, as well as from subjects who have wounds that do not show clinical signs of infection. swab samples will be collected from acute and chronic wounds of different etiologies and these will be analysed for bacteria types and markers of infection.


Eligibility criteria:
inclusion criteria: * subject has presented to participating study site with a wound(s) suspected to be infected, as determined by the investigator and/ or study staff - defined as one that through clinical judgment has questionable infection status, and /or shows three or more of the nerds or stones signs of infection); * subject has presented to participating study site with a wound(s) suspected not to be infected, as determined by the investigator and/ or study staff - defined as one that does not show three or more of the nerds or stones signs of infection. * subject is 18 years of age or older. * subject agrees to complete all aspects of the study and provides informed consent exclusion criteria: * subject is less than 18 years of age. * target wound contains a malignancy * subject has hypersensitivity of the wound or painful wound surface which prevents touching/swabbing of the wound surface. * subject is confirmed to be positive for hiv or hepatitis. * subject is unable or unwilling to provide informed consent. * subjects deemed inappropriate for the study by the site's principal investigator.

Keywords: chronic wounds with different etiologies diabetic foot ulcers venous leg ulcers pressure sores acute wounds
modified zhiwang decoction combined with methotrexate in the treatment of early rheumatoid arthritis

Conditions: Arthritis, Rheumatoid

Summary: the aim of this study is to evaluate the effectiveness and safety of modified zhiwang decoction in combination with methotrexate for the treatment of early ra patients and a parallel-group, single-center randomized controlled clinical study was designed.

rheumatoid arthritis(ra) is a progressive inflammatory autoimmune disease characterized by chronic systemic inflammation, which can cause swelling, stiffening and articular cartilage and bone destruction. early diagnosis and treatment in ra can improve outcomes and slow progression of joint damage. modified zhiwang decoction(mzwd) has great curative effects for treating ra. however, few randomized clinical trials(rcts) have evaluated the effectiveness of mzwd for the treatment of early ra. therefore, a parallel-group randomized controlled trial was designed to evaluate the efficacy and safety of mzwd combined with methotrexate on early ra.

Eligibility criteria:
inclusion criteria: * patients aged 16-70 years old; * patients who meet the diagnostic criteria of 2010 acr/eular . * patients who meet the diagnostic criteria of cold pattern. * disease activity score(das28) ≤5.2. exclusion criteria: * patients accompanied with other rheumatic diseases or severe pain due to other medical conditions, such as diabetic pain or post-herpetic neuralgia; * patients with joint dysfunction and the x-ray score of wrists is grade iv; * patients accompanied with mental and psychological disorders such as cognitive impairment, depression, anxiety, physical dysfunction, cerebral infarction, cerebral hemorrhage, epilepsy, tia, myelitis, demyelinating disease and other central nervous system diseases. * patients accompanied with organ injury or malignant tumors, disorders of the cardiovascular system, liver(alt/ast\>3 times higher than the upper limit of normal), kidneys(ccr\<60ml/min), brain, or hematopoietic system. * pregnant and lactating women. * patients are participation in any other clinical trials. * patients who are allergic to the drugs used in this study.
abiraterone-rechallenge study for crpc patients

Conditions: Prostate Cancer

Summary: to assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone.

to assess activity of abiraterone-re-challenge in patients with advanced prostate cancer and prior response to abiraterone. crpc patients with prior response to abiraterone (confirmed psa response) and progression can be re-challenged with abiraterone. patients may have received treatment with docetaxel, enzalutamide and radium-223.

Eligibility criteria:
inclusion criteria: 1. written prostate cancer. 2. adult patients with histological or cytological diagnosis of adenocarcinoma of the prostate. 3. men with castration-resistant metastatic decline maintained for at least 3 weeks as per pcwg2 criteria). 4. confirmed biochemical response to prior abiraterone acetate (≥50% psa informed consent (including consent for biomarker studies including the fresh tumour biopsies) 5. progressive disease according to pcwg2 criteria during prior therapy with standard dose of abiraterone acetate (confirmed increase of psa ≥25% over nadir) or soft-tissue or bone progression. patients that have stopped abiraterone acetate for reasons other than progression are not eligible. 6. documented progression of disease by any of the criteria listed here: * psa * soft tissue * bone scan all as per pcwg2 criteria 7. patients may have received treatment with docetaxel, enzalutamide or radium-223 8. psa of ≥10ug/l 9. ecog performance status 0 - 2 10. at least 3 months (90 days) since stop of prior abiraterone acetate. exclusion criteria: 1. major surgery within 28 days weeks prior to start of treatment 2. prior treatment with cabazitaxel or the cyp-17 inhibitor tak-700/orteronel 3. any concurrent treatment or prior treatment with an investigational drug within 28 days prior to start of treatment. 4. known brain or leptomeningeal disease 5. concurrent use of steroids other than prednisone \>10mg/d 6. inadequate bone marrow and organ function as evidenced by: platelet count \<75 x 10 g/l asat and/or alat ≥ 2.5 x uln total bilirubin ≥ 1.5 x uln (≥ 2.0 x uln for patients with gilbert's disease) hypokalaemia despite adequate supplementation creatinine clearance \<30ml/min 7. uncontrolled hypertension or cardiac failure or lvef \<50% creatinine clearance is to be calculated by using the formula of cockcroft-gault in appendix 4 of the protocol
theophylline for low adenosine syncope

Conditions: Syncope

Summary: the study aims at assessing that theophylline is effective in patients with no prodromes, normal heart and with low values of plasmatic adenosine compared with a propensity-score matched untreated control population who have received an implantable cardiac monitor (icm) for diagnosis of unexplained or atypical reflex syncope.

theophylline has been used for 3 decades in ordinary medical practice to tentatively prevent syncopal recurrences in patients affected by neurally-mediated syncope. observational studies report a recurrence rate with this drug ranging between 12% and 22%. theophylline was much more effective in selected patients with syncope without prodromes and normal heart who had ecg documentation of long pauses at the time of syncopal attack and low values of baseline plasmatic adenosine. since theophylline is a non-selective antagonist of purinergic receptors, it has been hypothesized that purinergic receptors are involved in the mechanism of syncope in such patients. conversely, theophylline was suspected to be ineffective (or less effective) in patients affected by other forms of neurally-mediated syncope. the present study aims at assessing that theophylline is effective in patients with no prodromes, normal heart and with low values of plasmatic adenosine compared with a propensity-score matched untreated control population. this will be a multicenter, non interventional study, verified by icm, with 2 predefined subgroups: subgroup #1 * low adenosine group: patients with low adenosine values (\<0.40 μmol/l) * normal/high adenosine (≥0.40 μmol/l) group: any other patient subgroup #2 * patients with no prodromes or very short prodromes (≤5 sec), normal heart and normal ecg (no prodrome group) * any other form of atypical neurally-mediated syncope with prodromes \>5 sec. remote or in-hospital periodic follow-up will be done according to centre's clinical practice for icm monitoring. patients will be followed up until the first primary endpoint event with a maximum follow-up of 24 months since start of theophylline treatment.

Eligibility criteria:
inclusion criteria: 1. male or female gender with age \>18 years 2. unexplained syncope without prodrome or neurally-mediated syncope with atypical prodrome, with normal heart and normal ecg 3. two syncopes /last year or 3 syncopes /last 2 years before start of theophylline treatment 4. having received an icm according to conventional guideline-based indications 5. being treated with oral theophylline therapy, while been waiting for icm diagnosis 6. having signed a written informed consent to the study participation and to the treatment of personal data exclusion criteria: 1. typical vaso-vagal syncope with long prodromes and situational syncope 2. any other form of syncope/t-loc different from reflex syncope 3. pregnant or breast-feeding patients -

Keywords: theophylline asystole implantable loop recorder
safety and pharmacokinetics of atezolizumab combination treatments in participants with her2-positive and her2-negative breast cancer

Conditions: HER2-Positive Metastatic Breast Cancer; HER2-Negative Metastatic Breast Cancer; Locally Advanced or Early Breast Cancer

Summary: this is a phase ib, open-label, two-stage study with two active regimens in each stage designed to evaluate the safety and tolerability of combination treatment with atezolizumab, trastuzumab, and pertuzumab (with and without docetaxel) or atezolizumab and trastuzumab emtansine in participants with human epidermal growth factor receptor 2 (her2) positive metastatic breast cancer (mbc) and locally advanced early breast cancer (ebc), and atezolizumab with doxorubicin and cyclophosphamide in her2-negative breast cancer.


Eligibility criteria:
inclusion criteria: * histologically documented her2-positive and her2-negative (cohort e only) breast cancer * metastatic breast cancer that is measurable (stage 1) or early breast cancer with a primary tumor size greater than (\>) 2 centimeter (cm) (stage 2) * eastern cooperative oncology group (ecog) performed status of 0, 1 or 2; 0 or 1 (cohort e only) * life expectancy of 12 or more weeks * adequate hematologic and end-organ function * left ventricular ejection fraction greater than or equal to (\>=) 50 percentage (%); \>=55% (cohort e only) exclusion criteria: * known central nervous system (cns) disease, except for treated asymptomatic cns metastases * leptomeningeal disease * pregnancy or lactation * history of autoimmune disease * prior allogeneic stem cell or solid organ transplantation * positive test for human immunodeficiency virus (hiv) * active hepatitis b or hepatitis c
cemented k-wire fixation vs plating for finger fractures

Conditions: Closed Fracture of Finger; Finger Fracture Open

Summary: to introduce a novel external-fixation technique using the combination of k-wires and cement. for comparison, we also included another group of patients who were treated using a mini plate and screw system. bone healing, range of motion of the fingers, costs of treatments, and patient satisfaction were assessed.

shaft fractures of the proximal phalanx are common injuries that may significantly affect hand function. good fracture stability to allow early mobilization of joints and thus early return of function. the objective of this report is to introduce a novel external-fixation technique using the combination of k-wires and cement. for comparison, we also included another group of patients who were treated using a mini plate and screw system. a total of 104 patients (131 fingers) were randomly allocated into group a (56 patients) and b (51 patients). patients in group a were treated with cemented k-wire fixation; and patients in group b were treated with conventional mini-plate. bone healing, range of motion of the fingers, costs of treatments, and patient satisfaction were assessed.

Eligibility criteria:
inclusion criteria: * patient aged between 18 and 65 years; * acute fractures within 15 days; * closed fracture or open injury with small wound less than 1.5 cm; * involvement of proximal phalanges of index to little fingers; shaft fractures; * at least 5 mm in length of the most distal and proximal fragments so that the k-wires or screws can be engaged; * oblique, spiral, and comminuted fractures; * normal opposite hand for comparison. exclusion criteria: * patients younger than 18 years are excluded because of skeletal immaturity; * patients older than 65 years are excluded because of possible osteoporosis; * severe open injury or crush injuries; tendon or neurovascular injuries; - involvement of articular surface; * old fractures exceeding 15 days because close reduction was most likely difficult; * a combined tendon, nerve, or artery injuries or diseases; diabetes, gout, ganglion; * osseous tumors, and other disease affecting bony structures and joint motion; * patients who declined to participate.

Keywords: reduction, fracture
growth retardation in children with special pathological conditions or disease

Conditions: Endocrine System Diseases

Summary: to show an increase in annual growth rate 3 years after visit 2. annual growth rate in standard deviation (sd) after 3 years will be compared to growth rate before the start of gh treatment.


Eligibility criteria:
inclusion criteria: * bone age \< 13 years for a boy and \< 11 years for a girl * naive child: measured height \< -2.5 sd for ca * child currently treated by gh exclusion criteria: * idiopathic short stature * syndrome known to be associated with an increased risk of cancer e.g. family history of adenomatous polyposis
study of the safety & efficacy of leukine® in the treatment of alzheimer's disease

Conditions: Alzheimer's Disease

Summary: a medicine that is fda-approved for bone marrow stimulation (called leukine) will be tested for its ability to be tolerated by alzheimer's disease patients and potentially to improve their memory.

preliminary preclinical results demonstrated that gm-csf (granulocyte macrophage colony-stimulating factor, e.g. leukine®/sargramostim) rapidly reduced cerebral amyloid deposition and completely reversed memory deficits in transgenic mouse models of alzheimer's disease (ad). to assess the efficacy of gm-csf in humans, the investigators performed a retrospective analysis of a cognition study of human patients undergoing hematopoietic cell transplantation for cancer and who garner cognitive impairments from the chemotherapy or irradiation. in the patients that received a colony-stimulating factor (csf) to stimulate the bone marrow and recover immune system function, the investigators found that those who received gm-csf (leukine®/sargramostim) plus g-csf (filigrastim) significantly improved in cognitive function as compared to those who received g-csf alone. these findings combined with over two decades of accrued safety data using recombinant human gm-csf, leukine®/sargramostim, in elderly leukopenic patients, suggested that leukine® should be tested as a treatment to reverse cerebral amyloid pathology and cognitive impairment in ad.

Eligibility criteria:
inclusion criteria: 1. age 55 to 85 years; 2. should have a mild-to-moderate ad diagnosis (mmse 10-26 inclusive); 3. should have evidence of elevated cortical amyloid by pet using florbetapir f18 (amyvid) \[i.e. a positive scan\], assessed qualitatively according to the amyvid product label. 4. if on anti-dementia treatment should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or memantine or axona); 5. stable on all other medications for at least 30 days prior to screen; 6. should be fluent in english; 7. should be physically able to participate by medical history, clinical exam and tests; 8. should have a study partner to accompany them to scheduled visits. exclusion criteria: 1. clinically relevant arrhythmias; 2. a resting pulse less than 50; 3. active cancer other than non-melanoma skin cancers; 4. use of another investigatory drug within 2 months of screening; 5. significant stroke or head trauma by history or mri; 6. contraindication for having a mri; 7. diagnostic and statistical manual of mental disorders-iv criteria for a current major psychiatric disorder; 8. sensitivity to yeast or yeast products; 9. impaired kidney function as measured by a glomerular filtration rate less than 60 milliliters/min; 10. preexisting fluid retention, pulmonary infiltrates, or congestive heart failure; 11. history of moderate-to-severe lung disease; 12. history of moderate-to-severe liver disease; 13. pregnant women, or any women who feel they are likely to become pregnant during the study; 14. prisoners.

Keywords: alzheimer's disease neuropsychological assessment granulocyte-macrophage colony-stimulating factor leukine
a research study looking at how semaglutide works in people with type 2 diabetes in italy, as part of local clinical practice

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how semaglutide works in real world patients. participants will get semaglutide prescribed to them by their doctor. the study will last for about 6 to 8 months. participants will be asked to complete some questionnaires about their health and your diabetes treatment. participants will complete these during their normally scheduled visits with their doctor.


Eligibility criteria:
inclusion criteria: * signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol) * the decision to initiate treatment with commercially available semaglutide has been made by the patient/legally acceptable representative and the treating physician before and independently from the decision to include the patient in this study * male or female, age 18 years or older at the time of signing informed consent * diagnosed with type 2 diabetes at least 12 weeks prior to inclusion * available and documented haemoglobin a1c (hba1c) value equal to or less than 12 weeks prior to initiation of semaglutide treatment exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study * mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation * treatment with any investigational drug within 90 days prior to enrolment into the study * hypersensitivity to semaglutide or to any of the excipients
registry of patients with plasma cell disorders

Conditions: Plasma Cell Disorders

Summary: the goal of this observational study is to register patients with plasma cell disorders. the main questions it aims to answer are: * the incidence of plasma cell disorders both before and after malignancy * time to progression of monoclonal gammopathy of undetermined significant (mgus) or smoldering multiple myeloma (smm) to light chain amyloidosis or multiple myeloma (mm) * progression free survival (pfs) * overall survival * factors influencing overall survival, progression-free survival, and time to progression * symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients. * genetic characteristics of plasma cell disorder * cost-effectiveness of treatment in thailand participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.


Eligibility criteria:
inclusion criteria: * both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, poems, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the international myeloma working group 2014 * aged 18 years and above exclusion criteria: * insufficient data needed for analysis

Keywords: registry plasma cell disorder
platelet rich plasma following hysteroscopic adhesolysis

Conditions: Intra-uterine Adhesions

Summary: platelet rich plasma following hysteroscopic adhesolysis: a randomized clinical trial


Eligibility criteria:
inclusion criteria: * age: 18-40 years * grade iii intra-uterine adhesions exclusion criteria: * age \ 40 years. * hb \< 11 g/dl, platelets \< 150.000/mm3. * patient taking anticoagulant. * patient taking nsaid in the 10 days before procedure. * any significant comorbidity or psychiatric disorder that would compromise patient's consent. * active cervical or uterine infection. * undiagnosed genital bleeding. * pregnancy.